NM_016169.4:c.210T>C
Variant summary
Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_016169.4(SUFU):c.210T>C(p.Tyr70Tyr) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000735 in 1,614,218 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_016169.4 synonymous
Scores
Clinical Significance
Conservation
Publications
- medulloblastomaInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), ClinGen
- nevoid basal cell carcinoma syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Illumina, Genomics England PanelApp
- basal cell nevus syndrome 2Inheritance: AD Classification: STRONG Submitted by: G2P
- ocular motor apraxia, Cogan typeInheritance: AD Classification: STRONG Submitted by: Franklin by Genoox
- Joubert syndrome 32Inheritance: AR Classification: STRONG, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
- Joubert syndromeInheritance: AR, AD Classification: MODERATE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics
- apraxiaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- ciliopathyInheritance: AR Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -21 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SUFU | ENST00000369902.8 | c.210T>C | p.Tyr70Tyr | synonymous_variant | Exon 2 of 12 | 1 | NM_016169.4 | ENSP00000358918.4 | ||
| SUFU | ENST00000423559.2 | c.210T>C | p.Tyr70Tyr | synonymous_variant | Exon 2 of 10 | 1 | ENSP00000411597.2 | |||
| SUFU | ENST00000369899.6 | c.210T>C | p.Tyr70Tyr | synonymous_variant | Exon 2 of 11 | 1 | ENSP00000358915.2 |
Frequencies
GnomAD3 genomes AF: 0.00387 AC: 589AN: 152234Hom.: 5 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00109 AC: 271AN: 249054 AF XY: 0.000764 show subpopulations
GnomAD4 exome AF: 0.000405 AC: 592AN: 1461866Hom.: 0 Cov.: 34 AF XY: 0.000366 AC XY: 266AN XY: 727234 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00390 AC: 594AN: 152352Hom.: 6 Cov.: 32 AF XY: 0.00342 AC XY: 255AN XY: 74508 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Benign:3
- -
SUFU: BP4, BS1 -
- -
not specified Benign:2
- -
Variant summary: SUFU c.210T>C alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0014 in 274742 control chromosomes, predominantly at a frequency of 0.014 within the African subpopulation in the gnomAD database, including 3 homozygotes. The observed variant frequency within African control individuals in the gnomAD database is approximately 13888-folds higher than the estimated maximal expected allele frequency for a pathogenic variant in SUFU causing Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome) phenotype (1e-06), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African origin. To our knowledge, no occurrence of c.210T>C in individuals affected with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome) and no experimental evidence demonstrating its impact on protein function have been reported. Three ClinVar submissions from clinical diagnostic laboratories (evaluation after 2014) cite the variant twice as benign and once as uncertain significance. Based on the evidence outlined above, the variant was classified as benign. -
Medulloblastoma;C3551915:Familial meningioma;C4540342:Joubert syndrome 32;C5830451:Basal cell nevus syndrome 2 Benign:1
- -
Gorlin syndrome;C0025149:Medulloblastoma Benign:1
- -
Medulloblastoma Benign:1
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. -
Hereditary cancer-predisposing syndrome Benign:1
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at